Resources from the same session
Vemurafenib (VM) in non-melanoma V600 and non-V600 BRAF mutated cancers: first results of the ACSE trial
Presenter: Jean-Yves Blay
Session: Basic science and translational research
Resources:
Abstract
Th1 epitopes as potential biomarkers for ipilimumab treatment
Presenter: Juan Marquez
Session: Basic science and translational research
Resources:
Abstract
Multidisciplinary molecular tumour board: a tool to improve clinical practice and selection accrual for clinical trials in cancer patients
Presenter: Christian Rolfo
Session: Basic science and translational research
Resources:
Abstract
MHC class II in lung cancer
Presenter: Yayi He
Session: Basic science and translational research
Resources:
Abstract
Lurbinectedin (PM01183) exhibits antitumor activity in PARP-inhibitor resistant germline BRCA PDX and lacks cross-resistance with cisplatin
Presenter: Cristina Cruz
Session: Basic science and translational research
Resources:
Abstract
Lenvatinib mesilate (LEN) enhanced antitumor activity of a PD-1 blockade agent by potentiating Th1 immune response
Presenter: Yu Kato
Session: Basic science and translational research
Resources:
Abstract
Invited discussant abstracts 56PD, 1159PD, 1521PD and 1581PD
Presenter: David Huntsman
Session: Basic science and translational research
Resources:
Presentation
Webcast
Invited discussant abstracts 2PD, 57PD and 58PD
Presenter: Dirk Schadendorf
Session: Basic science and translational research
Resources:
Presentation
Webcast
Invited discussant abstracts 1519O and 52O
Presenter: Sheila Singh
Session: Basic science and translational research
Resources:
Presentation
Webcast
Extended genotyping of RAS/BRAF for improved selection of metastatic CRC patients to anti-EGFR therapy: Comparison of three platforms
Presenter: Daniel Azuara
Session: Basic science and translational research
Resources:
Abstract